Drug recall · November 23, 2022
Fyarro (sirolimus protein-bound particles for injectable suspension recall
Why: Failed Stability Specifications
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Fyarro (sirolimus protein-bound particles for injectable suspension (albumin-bound), 100 mg per vial, NDC 80803-153-50, manufactured for Aadi Bioscience, Inc, CA.
- Lots / codes
Lot# 6025701, Expiration Date: 31MAR2023, 100mg/vial, 50 ml single use vial, NDC 80803-153-50.
- Quantity
- 2,333 vials
- Company
- Aadi Bioscience, Pacific Palisades, CA
- Distribution
- Within the U.S Market - PA, AL, KY, TN
- Initiated
- October 13, 2022 · Voluntary: Firm initiated
- Classified
- November 14, 2022
- Reported
- November 23, 2022
- Ended
- March 16, 2023
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Sirolimus
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.